COIOSDeep risk insights through multi-disciplinary research across the globe
Cityscape with river and bridge in the distance
Item refines Peer-reviewed Added

PSA density separates later prostate cancer risk after a negative screening MRI

Among 1,685 men with a negative screening MRI, seven-year incidence of significant prostate cancer was 5.5% below a PSA density of 0.10 ng/mL2 and more than double that above it.

A pre-specified sub-analysis of the randomised Goteborg-2 screening trial followed 1,685 men whose initial MRI was negative for a median of 5.5 years. At seven years, incidence of cancer graded Gleason 3+4 or worse was 5.5% where PSA density was below 0.10 ng/mL2. It was 13.8% at 0.10 to 0.15 and 11.9% above 0.15, with no further rise at the highest density.

Why it is interesting: Half the significant cancers after a negative MRI arose in men with the lowest PSA density.

Source
BJU International, 18 September 2026
Paper
The role of PSA density in the follow up of men with a negative MRI in the Göteborg-2 trial
Authors
Möller F, Månsson M, Hellström M, Langkilde F, Spyratou V, Stranne J et al.
DOI
10.1111/bju.70450
Type
Peer-reviewed article
Design
Pre-specified sub-analysis of the population-based randomised Göteborg-2 screening trial; 1685 men with a negative initial MRI, PSA testing 2015-2021, follow-up to September 2024 (median 5.5 years)
Verdict
Refines prior evidence
Driver
Cancer
Free full text
Free to read at the publisher
Attention
2 citations (Crossref) · as of 2026-11-05
Abstract — the authors' own words, CC BY

Objectives

To assess whether prostate-specific antigen density (PSAD) stratifies long-term risk of clinically significant prostate cancer (csPCa) after a negative magnetic resonance imaging (MRI; Prostate Imaging-Reporting and Data System score ≤2) and to evaluate the potential of PSAD to guide follow-up in a screening setting. Patients and methods

This pre-specified sub-analysis of the population-based, randomised Göteborg-2 screening trial included 1685 men who underwent PSA testing between October 2015 and June 2021 and had a subsequent negative initial MRI. Follow-up continued until 30 September 2024. The primary endpoint was cumulative incidence of csPCa (Gleason score ≥3 + 4). Men were categorised by baseline PSAD ( 2 ). Cumulative incidence was estimated using Kaplan-Meier methods and compared using the log-rank test. The clinical implications of PSAD-based follow-up strategies were explored. Results

Over a median follow-up of 5.5 years, 160 PCas were diagnosed, of which 80 were csPCa, including 22 cases of Gleason score ≥4 + 3. At 7 years, cumulative csPCa incidence was 7.1% overall and 5.5%, 13.8%, and 11.9% in the PSAD 2 groups, respectively (P 2 vs both higher groups). Overall, 87% of repeat MRIs remained negative. Although men with baseline PSAD 2 had the lowest overall risk, 42 csPCas occurred in this group, including 12 Gleason score ≥4 + 3, emphasising the importance of continued regular PSA-based follow-up. A PSAD-guided strategy with biennial PSA testing and repeat MRI triggered by PSAD ≥0.10 ng/mL 2 could reduce MRI use by 60% and biopsies by 46%, halve detection of clinically insignificant PCa, and delay csPCa diagnosis in 17% of cases including 10 men with Gleason score 3 + 4 and one with Gleason score ≥4 + 3. Conclusions

The PSAD stratifies long-term risk of csPCa after a negative MRI and supports risk-adapted follow-up in PCa screening.

Other drivers in Health today